Miriam T Jacobs

7PUBLICATIONS
77CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsInnate immunityApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Aug 02, 2024
Five-Year Follow-Up of Standard-of-Care Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium.

Michael D Jain, Jay Y Spiegel, Loretta J Nastoupil

|Aug 09, 2023
Memory-like Differentiation, Tumor-Targeting mAbs, and Chimeric Antigen Receptors Enhance Natural Killer Cell Responses to Head and Neck Cancer.

Miriam T Jacobs, Pamela Wong, Alice Y Zhou

|Feb 08, 2023
Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium.

Yucai Wang, Preetesh Jain, Frederick L Locke

|Nov 23, 2022
Allogeneic natural killer cell therapy.

Melissa M Berrien-Elliott, Miriam T Jacobs, Todd A Fehniger

|Feb 23, 2022
Hematopoietic cell transplantation donor-derived memory-like NK cells functionally persist after transfer into patients with leukemia.

Melissa M Berrien-Elliott, Jennifer A Foltz, David A Russler-Germain

|Nov 19, 2021
Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy.

Melissa M Berrien-Elliott, Michelle Becker-Hapak, Amanda F Cashen

Pageof 2

Frequent Collaborators

5 joint publications

Melissa M Berrien-Elliott

4 joint publications

Todd A Fehniger

4 joint publications

Pamela Wong

3 joint publications

Nancy D Marin